Nosopharm and Evotec SE have entered a partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.  NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins (ODLs). NOSO-502 has proven to be effective in vivo in Enterobacteriaceae infection models and demonstrated antibacterial activity in vitro against multi-drug resistant clinical isolates (KPC, NDM and ...